Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance

Blood. 2014 Dec 11;124(25):3831-3. doi: 10.1182/blood-2014-08-592725.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Agammaglobulinaemia Tyrosine Kinase
  • Alleles
  • Cohort Studies
  • DNA Mutational Analysis
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / enzymology
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Mutation*
  • Piperidines
  • Polymerase Chain Reaction / methods
  • Protein-Tyrosine Kinases / genetics*
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*

Substances

  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Protein-Tyrosine Kinases
  • Agammaglobulinaemia Tyrosine Kinase
  • Adenine